Mangafodipir as a cytoprotective adjunct to chemotherapy a case report

Acta Oncologica

Volumn 48, Issue 4, 2009, Pages 633-635

  Yri, Olav Erich ^a   Vig, Jens ^a   Hegstad, Elisabeth ^a   Hovde, Øistein ^a   Pignon, Ingrid ^a   Jynge, Per ^b  

^a INNLANDET HOSPITAL TRUST   (Norway)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINATE CALCIUM; IRINOTECAN; MANGAFODIPIR; OXALIPLATIN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; EDETIC ACID; FOLINIC ACID; N,N' BIS(PYRIDOXAL 5 PHOSPHATE)ETHYLENEDIAMINE N,N' DIACETIC ACID; N,N'-BIS(PYRIDOXAL-5-PHOSPHATE)ETHYLENEDIAMINE-N,N'-DIACETIC ACID; PYRIDOXAL 5 PHOSPHATE;

ADULT; ANAMNESIS; BED REST; CASE REPORT; CELL PROTECTION; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; HEMICOLECTOMY; HUMAN; LABORATORY TEST; LETTER; LIVER METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; BLOOD; COLON RESECTION; COLON TUMOR; CROHN DISEASE; METHODOLOGY; PALLIATIVE THERAPY; SCLEROSING CHOLANGITIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHOLANGITIS, SCLEROSING; COLECTOMY; COLONIC NEOPLASMS; CROHN DISEASE; CYTOPROTECTION; EDETIC ACID; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; PALLIATIVE CARE; PYRIDOXAL PHOSPHATE; YOUNG ADULT;

EID: 65549100188     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802680427     Document Type: Letter

References (9)

1. Brurok H, Ardenkjær-Larsen JH, Hansson G, et al. Manganese dipyridoxyl diphosphate: MRI contrast agent with antioxidative and cardioprotective properties. Bioch Biophys Res Comm 1999;/254:/768-72.
2. Karlsson JOG, Brurok H, Towart R, Jynge P. Letter to the Editor. The magnetic resonance imaging contrast agent mangafodipir exerts antitumor activity via a previously described superoxide mimetic activity. Cancer Res 2006;/66:/ 598.
3. Towart R, Jynge P, Refsum H, Karlsson JOG. Manganese dipyridoxyl diphosphate protects against acute anthracycline induced cardiotoxicity in mice. Arch Pharmacol 1998;/ 358(Suppl 2):/R626.
4. Laurent A, Nicco C, Chéreau C, Goulvestre C, Alexandre J, Alves A, et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 2005;/65:/948-56.
5. Alexandre J, Nicco C, Chéreau C, Laurent A, Weill B, Goldwasser F, et al. Improvement of the thereapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst 2006;/98:/236-44.
6. Sørbye H, Dahl O. Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. Acta Oncol 2003;/42:/827-31.
7. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;/18:/2938-47.
8. Shimizu T, Satoh T, Tamura K, et al. Oxaliplatin /fluorouracil/ leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: Postapproval Japanese population experience. T Oncol 2007;/12:/ 218-23.
9. Crossgrove J, Zheng W. Manganese toxicity upon overexposure. NMR Biomed 2004;/17:/544-53.